The accumulation of somatic mutations in a genome is the result of the activity of one or 15 more mutagenic processes, each of which leaves its own imprint. The study of these DNA 16 fingerprints, termed mutational signatures, holds important potential for furthering our 17 understanding of the causes and evolution of cancer, and can provide insights of relevance for 18 cancer prevention and treatment. In this review, we focus our attention on the mathematical 19 models and computational techniques that have driven recent advances in the field. 20 21 Key words: mutational signatures; mathematical modelling; computational methods; cancer 22
Introduction 23
Cancer is a disease of the genome, in which uncontrolled clonal proliferation is initiated and 24 fuelled by genomic alterations in somatic cells [1] . Despite the fact that a cancer genome may 25 carry between tens and millions of somatic mutations [2, 3] , only a small subset of these, 26
termed 'driver' mutations, are thought to be under selection and to cause neoplastic expansion 27 [1, 4] . The remaining 'passenger' mutations are generally believed not to confer selective 28 advantage, and to arise from the processes involved in mutagenesis [5, 6] . The collection of 29 mutations in a somatic cell genome is the result of one or more mutational processes 30 operating, continuously or intermittently, during the organism's lifetime [7] . Such mutational 31 processes include DNA damage by exogenous or endogenous agents, defective DNA 32 replication, insertion of transposable elements, defects in DNA repair mechanisms, and 33 enzymatic modifications of DNA, among others [8] . Many of these processes imprint a 34 distinct pattern of mutations in the genome, known as a 'mutational signature' [2, 9] . 35 Therefore, the compendium of somatic changes in a cancer genome constitutes a record of the 36 combined mutagenic effect of the specific mixture of processes moulding it [2] . Furthermore, 37 because most mutations are passengers, they are largely beyond the effect of adaptive 38 selection [10] . 39
Although mutational signatures are a relatively recent concept in cancer biology, the 40 first descriptions of genomic aberrations caused by a specific process date back to the early 41 twentieth century, when X-rays were found to induce chromosome breakage in irradiated 42 cells [11] [12] [13] . More-detailed mutational patterns were reported in the 1960s, notably the 43 crosslinking of adjacent pyrimidine bases (CC, CT, TC, TT) due to ultraviolet radiation, 44 which produces cytosine-to-thymine (C>T) and cytosine-cytosine-to-thymine-thymine 45 (CC>TT) transitions at dipyrimidine sites [14] [15] [16] . Other causal links between mutagenic 46 agents and patterns of somatic changes have also become established, such as the guanine-to-47 thymine (G>T) transversions resulting from guanine adducts that are caused by carcinogens 48 present in tobacco smoke [17, 18] . Furthermore, some chemotherapeutic agents are mutagens 49 as well, and may imprint their own mutational signature in the cancer genomes of patients 50 with secondary malignancies [19, 20] . These examples illustrate the importance of studying 51 somatic mutation patterns to our understanding of the molecular mechanisms of neoplasia, 52 potentially enabling the discovery of novel mutagens [2, 7, 8, 21] . Moreover, several authors 53 have emphasised the potential of mutational signature analysis to provide insights of clinical 54 significance, by informing and guiding diagnostic procedures, personalised cancer 55 interventions and prevention efforts [19, [22] [23] [24] [25] [26] [27] . 56 indels [29, 32] or structural variants [27, 29, 32] have also been described. Furthermore, certain 77 substitution signatures are consistently associated with features such as increased numbers of 78 indels or rearrangements of a particular class, kataegis events, or biases in the transcriptional 79 strand in which mutations occur [2, [28] [29] [30] 33] . It is therefore useful to consider such features 80 as biological constraints for the identification of signatures, even if precisely modelling them 81 is more challenging. 82
The selected set of K mutation types can be expressed as a finite alphabet , with 83 = K, every symbol in representing a distinct mutation type. This alphabet constitutes 84 the domain of a mutational signature, which is modelled as a discrete probability density 85 function, S : → ℝ + K . Hence, the mathematical representation of a given signature, S n , is a K-86 tuple of probability values, S n = [s 1n , s 2n , …, s Kn ] T , with s kn denoting the probability of the 87 mutation type represented by the k-th symbol in A being caused by the mutational process 88 associated with S n . As probability values, the elements of S n are intrinsically nonnegative and 89 their sum is always 1: 90 (1) s kn ≥ 0, 1 ≤ k ≤ K
(2)
The same mutational process operating in multiple genomes may produce different 91 numbers of mutations in each. The intensity at which a mutational process with signature S n 92 operates in a genome g, expressed in terms of the number of mutations caused, is known as 93 the 'exposure' to (or the 'contribution' or 'activity' of) the process, and denoted by e ng . 94
Regarding the catalogue of somatic mutations in a cancer genome g, this is also defined as a 95 vector of mutation counts over , M g ∶ → ℕ 0 K , and expressed as a second nonnegative K-96 are first classified into six categories, by representing the change at the pyrimidine partner in 110 the mutated base pair (e.g. a guanine-to-adenine substitution, G>A, is instead expressed as a 111 cytosine-to-thymine change, C>T, in the complementary strand). This classification is then 112 extended by considering the immediate sequence context of the substitution, usually the 113 adjacent 5' and 3' bases. The six substitution types are thus translated into 96 trinucleotide 114 mutation types (6 substitution types × 4 types of 5' base × 4 types of 3' base). An extensive 115 literature supports the need for at least a trinucleotide context of mutations in order to 116 distinguish the mutational patterns induced by a variety of mutagens. In addition, there have 117 been attempts to deconvolute signatures using a five-or seven-base sequence context, 118 resulting in 1536 and 24,576 mutation types, respectively [27, 34, 35] . Further elaboration can 119 also be achieved by considering the transcriptional strand of mutations in transcribed regions. 120
Nevertheless, expanding the range of mutation types normally implies a decrease in the 121 observed number of mutations per type, which may curb the power to identify patterns. 122
In a generalisation that considers N different mutational processes acting in a 123 collection of G cancer genomes, with mutational catalogues defined over K mutation types, 124 the catalogues, signatures and exposures can be mathematically expressed as matrices named 125
Consequently, the approximate description of a mutational catalogue as a sum of 127 signatures multiplied by their exposures, expressed in (3), is generalised into matrix form: 128
components and the mixture coefficients, and that no orthogonality or independence 147 constraints are imposed (therefore permitting partially or entirely correlated components). 148
These features make NMF especially well-suited to the problem of mutational signature 149 inference, because of the intrinsic nonnegativity of the matrices in the mathematical model 150 
The algorithm first initialises S and E as random nonnegative matrices, and reduces 166 the dimension of M by removing those mutation types that together account for ≤1% of all the 167 mutations. Two steps are then iteratively followed: (a) Monte Carlo bootstrap resampling of 168 the reduced catalogue matrix, and (b) application of the multiplicative update algorithm to the 169 resampled matrix, finding the instances of S and E that minimise the Frobenius norm in (5). 170
After completion of the iterative stage, partition clustering is applied to the resulting set of 171 signatures, in order to structure the data into N clusters. The N consensus signature vectors, which compose the averaged signature matrix, S, are obtained by averaging the signatures in 173 each cluster. Since each signature is related to a specific exposure, the averaged exposure 174 matrix, E, can be inferred from S. In cases where the mutational catalogues have been derived 175 from cancer exomes, the extracted mutational signatures should thereafter be normalised to 176 the trinucleotide frequencies of the whole genome. 177
The WTSI Framework requires the number of signatures to infer, N, to be defined as 178 a parameter. Because the number of signatures present in the data is normally not known a 179 priori, the framework needs to be applied for values of N ranging between 1 (or the smallest 180 Although the NMF approach has proven highly effective, especially when applied to 192 large cohorts of cancer genomes, it is not without conceptual limitations [34] . The first of 193 these lies in the number of catalogues required, which is a limiting factor on the number of 194 signatures that can be accurately extracted, and rises exponentially with N. The number of 195 mutations per catalogue also influences the power to infer signatures, with a small set of 196 densely mutated genomes being more informative than a large number of sparsely mutated 197 genomes. In fact, the influence of catalogues with extreme mutation burdens (hypermutated 198 genomes) on the NMF process can hinder the detection of signals from less-mutated 199 catalogues. Furthermore, mutational signatures exhibiting higher exposures can generally be 200 identified more easily and accurately. Sensitivity to initial conditions is another major 201 limitation, arising from the high dimensionality and inherent nonconvexity (presence of 202 multiple local minima) of the optimisation problem posed by (5). This aspect of NMF has 203 attracted particular attention in the past, leading to the proposal of alternative initialisation 204 strategies [46, 47] that might outperform the random initialisation adopted by the WTSI 205
Framework. 206
In more recent analyses, the WTSI working group has significantly refined their own 207 application of the WTSI Framework, in order to enhance power and accuracy; however, such 208 refinements have not been incorporated in the publically available software. Firstly, an 209 additional analysis step can follow the deconvolution of consensus mutational signatures, 210 which centres on precisely estimating the contribution of each signature to each genome [28] . 211 This is individually achieved for each catalogue through minimisation of a variation of the 212 function shown in (5); the difference lies in S now being known, and harbouring only the 213 consensus mutational patterns of the processes that operate in the tumour type of the sample 214 (these are known from the signature extraction process). Notably, additional biological 215 constraints are imposed in the selection of the processes included in S; these require that, for 216 each candidate process, at least one associated genomic feature (e.g. transcriptional strand 217 bias or enrichment in aberrations of a specific type) be present in the examined sample. The 218 second enhancement consists of a 'hierarchical signature extraction' process [29] , which is 219 directed to increase the power to identify signatures exhibiting either low activity or limited 220 representation across the sample cohort. Here, the WTSI Framework is initially applied to the 221 original matrix, M, containing all the somatic catalogues. After identification of signatures, 222 those samples that are well-explained by the resulting mutational patterns are removed from 223 M, and the method is re-applied to the remaining catalogues. The process is repeated until no 224 new signatures are discovered, and the additional step for estimating signature contributions 225 described above is then applied to all the consensus patterns. Although both SomaticSignatures and MutSpec ultimately apply the same 248 implementation of the multiplicative update algorithm for NMF [38] originally adopted by the 249 WTSI Framework, it should be noted that these packages may not produce identical results to 250 those of the latter, since they lack the computationally intensive pre-processing and 251
bootstrapping routines that complement the application of NMF in the method devised by 
Expectation-maximisation 260
In contrast to the numerical optimisation approach to mutational signature inference 261 expressed by (5), probabilistic frameworks have also been devised which exploit the 262 intrinsically stochastic nature of mutagenesis. These frameworks have been claimed to be 263 better-suited to deal with mutational stochasticity, which is partly responsible for the noise 264 observed in mutational catalogues and becomes more prominent as less-mutated genomes, or 265 smaller genomic regions, are examined. 266
The first probabilistic approach in the field was developed by Another novelty of EMu is the incorporation of tumour-specific variation in 277 mutational opportunity across different sequence contexts. Mutational opportunities, which 278 derive from the sequence composition of a genome, can be expressed as a nonnegative K-279 tuple containing the opportunity for each mutation type in the genome g,
For single-base substitutions in a trinucleotide context, the 281 opportunities correspond to the frequencies of each trinucleotide type in each genome. 282
Explicitly accounting for the opportunity for mutations to occur is especially relevant given 283 that the relative frequency of certain sequences in the human genome (e.g. 284 underrepresentation of CpG dinucleotides) can exert undesired biases on the inferred 285 mutational patterns. In addition, copy number alterations, which are frequent in cancer 286 genomes [1, 67] , can substantially alter the mutational opportunity in affected regions across 287 tumours. The divergence in sequence composition across genomic segments also makes 288 opportunity a relevant factor in the determination of signature contributions in a specific 289 region. The probabilistic framework and explicit dependence on opportunity are intended to 290 increase adaptability for the analysis of signatures in short genomic regions. 291
Fischer et al. make use of a Poisson-distributed probabilistic model to describe the 292 mutational catalogue of a given genome as the result of a stochastic process of mutation 293 accumulation. Assuming the N mutational processes to be mutually independent, the 294 probability of observing the catalogue M g = [m 1g , m 2g , …, m Kg ] is given by: 295
In this model, the mutational signatures, S, act as the shared model parameters, and 296 the signature exposures, E, as the hidden data. The end of the EM procedure is to find 297 maximum likelihood estimates of both, thereby solving the deconvolution problem. The 298 algorithm starts by making an initial guess of the model parameters, S (0) , and thereafter 299 iterates through two steps. In the first, denoted E-step, an estimate is obtained for the 300 signature exposures, E, given the current parameter guess, S (k) . In the subsequent M-step, E is 301 used to update the parameter estimate for the next iteration, S (k+1) . Iteration through these 302 steps finishes when the likelihood of the observed data, p(M|S), converges to a local 303
maximum. 304
The data likelihoods obtained for different values of N are compared in order to 305 determine the number of mutational processes involved. Because increasing N normally leads 306 to a better explanation of the data, due to the higher number of available model parameters, 307 the likelihood generally rises with N. Overfitting of the data is avoided applying the Bayesian 308 information criterion (BIC) [68], a model selection criterion whose second term corrects for 309 the model complexity: 310
The BIC is calculated for each of the models, and the one exhibiting the highest BIC 311 properties of the EM paradigm, but explicit enhancements that are amenable to assimilation 321 by other approaches. On the other hand, EMu suffers from the same sensitivity to initial 322 conditions as conventional NMF, and it may as well benefit from alternative initialisation 323 strategies. Despite this, EMu successfully exploits a probabilistic formulation of mutational 324 signature inference to address previously unexplored aspects, namely the incorporation of 325 context-and tumour-specific opportunity for mutations, the estimation of local signature 326 exposures, and the direct determination of the number of mutational processes. assumed to be the result of a two-step generative model: first, a mutational signature is 443 selected according to the membership parameters of the current catalogue; second, the 444 features of the mutation are generated according to the multinomial distribution described by 445 the chosen signature. Of note, informative parallelisms between NMF and admixture models 446 have been previously noted by other authors [81], suggesting that current methods could 447 benefit from the experience gained in applications of the latter. 448
The central parameters of the independent model, namely the sample membership 449 proportions, q gn , and the signature parameters, F n , need to be estimated from the observed 450 catalogues; this is done by means of an EM algorithm [66] . In order to account for the 451 tendency of EM to converge to different local maxima depending on the initial conditions, the 452 algorithm is applied on multiple initial configurations, before choosing the solution that 453 exhibits maximum likelihood overall. To model mutational opportunity, instead of using 454 probabilistic coefficients, pmsignature employs a 'background signature' corresponding to the 455 genome frequencies of the types of nucleotide association considered (e.g. pentanucleotides). 456
However, this background signature is based on the human reference genome, thus negating 457 incorporation of sample-specific variegation in opportunity. Regarding the estimation of the 458 number of mutational processes, an analogous strategy to that implemented by Alexandrov et 459 al.
[34] is adopted, with N being manually chosen such that the likelihood is sufficiently high, 460
and the standard errors of the parameters are sufficiently low. In addition, N is selected such 461 that the resulting set of mutational signatures does not contain any pair of signatures which 462 seem to correspond to the same mutational process (signatures exhibiting similar feature 463 patterns and membership parameters). Hence, a more versatile strategy to automatically 464 determine N would constitute a major improvement of the method. unknown. Because S is known a priori, signature refitting is a much more tractable problem 493 than de novo signature inference. In consequence, signature refitting does not suffer the 494 requirement of large sample cohorts to achieve power and accuracy, being even applicable to 495 individual genomes. 496
The deconstructSigs R package, recently developed by Rosenthal et al. [86] , is 497 currently the only published method explicitly designed for mutational signature refitting. It 498 adopts an iterative multiple linear regression strategy to estimate the linear combination of 499 signatures that optimally reconstructs the mutational profile of each genome in M, imposing 500 nonnegativity on the inferred signature exposures. Mutational catalogues are modelled as 501 mutation proportions, instead of counts, and normalisation by mutational opportunity is 502 enabled through the incorporation of the trinucleotide frequencies from the reference human 503 genome. The iterative fitting algorithm, which is applied separately to each catalogue, starts 504 by discarding those signatures in which a mutation type that is absent from the examined 505 catalogue has a probability above 0.2. This prevents consideration of signatures that, 506 according to their mutational profiles, are unlikely to be present in the tumour. An initial 507 signature is then selected, such that the sum of squared errors (SSE) between the signature 508 and the mutational profile of the catalogue is minimised. The exposure value that minimises 509 the SSE for the chosen signature is set as the only positive exposure. In successive iterations, 510 each of the remaining signatures is evaluated to find the exposure value that minimises the 511 SSE between the reconstructed profile (including the previously incorporated exposures and 512 the candidate one) and the mutational profile of the tumour. The signature achieving 513 minimum SSE is selected, and its optimal exposure is incorporated to the reconstructed 514 profile. The process continues until the difference in SSE before and after an iteration falls 515 below an empirically determined threshold of 10 -4 ; the estimated exposures are then 516 transformed to proportions. Finally, any exposure lower than 0.06 (6%) is discarded, in order 517 to exclude spurious signatures; this minimum exposure threshold was also empirically 518 determined from simulation studies. 519
An iterative regression strategy has important associated risks, the most prominent 520 being the impossibility of reducing or removing the contribution of a signature after it has 521 been selected. Consequently, a signature that is actually absent from the sample might be 522 unalterably chosen in the initial iterations, only because it fits the overall profile of the tumour 523 better than any other signature. This is not a rare situation, since one-third of the currently 524 and demonstrated by the number of studies that have adopted their method in the short time 539 since its publication [54, [87] [88] [89] [90] . When used for refitting well-validated signatures in specific 540 cancer types, deconstructSigs has the power to detect mutational processes that operate only 541 in small subsets of genomes, without the complexity or requirement of large cohorts that 542 characterise de novo approaches. Some remarkable applications are the comparison between 543 processes operative across different cancer subtypes, and the analysis of variegation in 544 signature activities over time within a single tumour, or between primary and metastatic sites 545 in a same patient. As genomic examination of individual malignancies is gradually 546 incorporated into clinical practice, a straightforward method to ascertain which mutational 547 processes operate in a cancer genome, and to what extent, potentially including their temporal 548 and spatial evolution, will constitute an invaluable instrument for the advancement of 549 personalised cancer therapy. 550 551
Alternative approaches 552
Apart from the ones described here, both de novo inference and refitting of mutational 553
signatures are amenable to many other computational approaches, including purely Bayesian 554 techniques (e.g. hierarchical Dirichlet processes), global optimisation metaheuristics (e.g. 555 simulated annealing), and nonlinear optimisation algorithms (e.g. sequential quadratic 556 programming). When considering the design of novel methods for the analysis of mutational 557 signatures, the special properties of each technique, such as propensity for overfitting, 558 sensitivity to initial conditions, computational cost and scalability, should be thoughtfully 559 considered. In the near term, fresh methodologies are likely to arise which build upon either 560 the mathematical models of signatures already developed, or entirely new ones. Furthermore, 561 because signature refitting poses a much simpler mathematical problem than de novo 562 signature deconvolution, approaches based on well-established mathematical or statistical 563 paradigms could be implemented with little effort, as substantiated by works that have already 564 accomplished signature refitting through some of the aforementioned techniques [27, 91, 92] . 565 566 Discussion 567
In the relatively short time since its first reported application [33, 43] , the deconvolution of 568 mutational signatures has proven a successful analytical technique. Numerous authors have 569 highlighted the potential of mutational signature analysis in the settings of cancer treatment 570 and prevention. The proposed applications thus far include the use of signatures (a) as genetic 571 biomarkers of early malignancy or exposure to carcinogenic agents, especially in combination 572 with 'liquid biopsy' diagnostic techniques [23, 26] ; (b) to stratify patient cohorts into 573 subgroups indicative of distinct dominant aetiological factors, with the aim of suggesting 574 targeted therapies that may benefit some subgroups, on the basis of the molecular 575 mechanisms involved [19, 22, 24, 27, 93] ; (c) to discover or support causative links between 576 exposure to known or novel carcinogens and the development of particular cancer types, by 577 determining the extent to which those carcinogens contribute to mutagenesis [25, 26, 94, 95] ; 578 (d) to evaluate the safety of chemotherapeutic agents, some of which have been shown to 579 contribute to the mutation burdens in exposed patients [19, 20] ; (e) to drive novel molecular 580 research directed at establishing links between mutagens or molecular processes and currently 581 unexplained ('orphan') signatures [19] , or to tease apart the individual fingerprints hidden in 582 composite mutational patterns, such as that of the complex chemical mixture in tobacco 583 between some of these methods and reported notable coherence between their outcomes, in 607 spite of their divergent mathematical frameworks. Other approaches, while still adhering to 608 the classic NMF formulation, intend to facilitate signature analysis by means of user-friendly 609 graphical interfaces [57] or integration in popular bioinformatic frameworks [48] . As a 610 mounting number of medium-scale studies aspire to probe the mutational mechanisms 611 operating in specific cancer types or subtypes, methods that enable simple and accurate 612 analysis of signatures are definitely welcome contributions to the field. 613
The identification of mutational signatures in cancer genomes remains a daunting 614 endeavour, despite the breakthroughs it has spurred. In the short term, some of the 615 computational strategies reported here will likely be subjected to significant refinement, or 616 extended through the release of new software, while fresh approaches to signature discovery, 617 using yet-unexploited techniques, are also sure to arrive. In the longer term, it must be noted 618 that current methods base their signature models exclusively on mutational profiles, and fail 619 to incorporate other experimental and clinical knowledge about mutational processes. Instead, 620 current studies rely on a manual, informal consideration of the additional biological features 621 associated with certain signatures. Such features should be quantified and formally 622 accommodated in mathematical models, if methods for identification are to be further sharpened. At the same time, the pursuit of high-resolution mutational signatures by 624 accounting for additional contextual features might be hindered by the limitations of current 625 models. It can be argued that innovative models assuming niether complete mutual 626 independence nor non-independence between the features of a signature could prove key to 627 achieving the ideal compromise between flexibility and complexity that is warranted for 628 powerful, stable and accurate delineation of mutational signatures. 629
As current and forthcoming approaches shed light on the mathematical properties of 630 mutational signature discovery, the study of somatic mutation patterns will surely be extended 631 through the addition of new signatures, aberration classes, contextual features, and previously 632 unexamined cancer types. Meanwhile, the insights yielded by advances in this field will 633 further our understanding of the causes, mechanisms and evolution of human malignancy, and 634 provide new opportunities for cancer prevention and treatment. 635 636 Key points 637
• The somatic mutations in a genome are the result of the activity of one or more 638 mutational processes, some of which imprint a distinct mutational signature. 639
• Nonnegative matrix factorization (NMF) is the most widely used method for 640 identifying mutational signatures. 641
• Alternative approaches include partly and fully probabilistic models, as well as NMF 642 implementations offering greater ease of use. 643
• The study of mutational signatures can prove useful for cancer prevention and 644 treatment efforts, including patient stratification and identification of novel mutagens. 645
• The field will likely be expanded with the inclusion of additional techniques, mutation 646 classes, biological features and tumour types. illustrating the modelling of mutational signatures as probabilistic relationships between mutation 659 types and mutational processes operative in genomes, for a general case with K mutation types, N 660 mutational processes and G genomes. The notation of signatures, exposures and mutational 661 catalogues follows that used in the main text. The varying widths of the links between mutation 662 types and signatures (mutation probabilities), and between signatures and catalogues (signature 663 exposures) represent the observation that varying values of s kn and e ng reflect the specific 664 mutational profile of each signature and the exposure composition of each genome. Nonnegativity 665 constraints for mutation probabilities and signature exposures are specified directly below them. 666 (b) Example of de novo signature extraction, for a case with K = 6 mutation (single-base 667 substitution) types, N = 3 mutational signatures and G = 4 mutational catalogues. Starting from the 668 set of catalogues (depicted here as mutational profiles, each bar corresponding to a distinct 669 mutation type), de novo extraction methods determine the set of mutational signatures 670 (represented as consensus mutational profiles) and exposures (depicted here as proportions of the 671 mutations in each catalogue, for simplicity) that reconstruct the original mutational catalogues 672 with minimal error. 673 
